Showing results (141-150 of 150) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 150 results.
European Urology|July 20, 2020
FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment?†Bas W G van Rhijn, Laura S Mertens, Roman Mayr, et al.
Lancet (London, England)|December 13, 2016
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trialArjun V Balar, Matthew D Galsky, Jonathan E Rosenberg, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 20, 2016
Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatmentD Pouessel, Y Neuzillet, L S Mertens, et al.
Lancet (London, England)|September 17, 2017
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trialDaniel P Petrylak, Ronald de Wit, Kim N Chi, et al.
Nature|February 15, 2018
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cellsSanjeev Mariathasan, Shannon J Turley, Dorothee Nickles, et al.
Cancer Discovery|June 13, 2024
Cancer Core Europe: Leveraging Institutional Synergies to Advance Oncology Research and Care GloballyJavier Carmona, Elena Chavarria, Kate Donoghue, et al.
Urologic Oncology|December 15, 2021
Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patientsLaura S Mertens, Francesco Claps, Roman Mayr, et al.
The Lancet. Oncology|November 23, 2019
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trialDaniel P Petrylak, Ronald de Wit, Kim N Chi, et al.
CA: a Cancer Journal for Clinicians|December 13, 2025
Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancersRana R McKay, Sumanta Pal, Wanling Xie, et al.
Cancer Discovery|August 5, 2022
Escherichia coli-Specific CXCL13-Producing TFH Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder CancerAnne-Gaëlle Goubet, Leonardo Lordello, Carolina Alves Costa Silva, et al.
Pageof 15